Table 2 Baseline clinical variables of participants.
Variables | Categories | Survival Status | Total | Chi-square test | p-values | |
|---|---|---|---|---|---|---|
Censored (%) | Event (%) | |||||
Adherence | Poor Fair Good | 7(43.75) 43(49.43) 175(58.33) | 9(56.25) 44(50.57) 125(41.67) | 16 87 300 | 186.875 | 0.000 |
WHO clinical stage | Stage-I Stage-II Stage-III Stage-IV | 114(50.89) 53 (68.83) 47(63.51) 11 (39.29) | 110(49.11) 24(31.17) 27(36.49) 17 (60.71) | 224 77 74 28 | 12.372 | 0.006 |
ART regiment | 1c(AZT-3TC-NVP) 1d(AZT-3TC-EFV) 1e(TDF-3TC-EFV) 1f.(TDF + 3TC + NVP) 1j(TDF + 3TC + DTG) Other | 42(61.76) 39(88.64) 78(40.84) 26(81.25) 13(48.15) 27 (65.85) | 26(38.24) 5(11.36) 113(59.16) 6(18.75) 14 (51.85) 14(34.15) | 68 44 191 32 27 41 | 48.285 | 0.000 |
TB screen | No Yes | 216(62.25) 9(16.07) | 131(37.75) 47(83.93) | 347 56 | 41.693 | 0.000 |
OIs | No Yes | 198(61.68) 27( 32.93) | 123(38.32) 55(67.07) | 321 82 | 21.901 | 0.000 |
OCC | No Yes | 203(64.65) 22 (24.72) | 111(35.35) 67(75.28 ) | 314 89 | 44.837 | 0.001 |
Total | 225(55.8) | 178(44.2) | 403 | |||
